Results for mastitis translation from English to Maltese

acute mastitis.
mastite akuta.

breast inflammation/mastitis
infjammazzjoni tas-sider/mastite

the relative reduction in mastitis incidence was 26%.
it-tnaqqis relattiv fl-inċidenza tal-mastite kien ta' 26%.

the experimental design of the study mimicked acute toxic mastitis.
id- disinn sperimentali ta ’ l- istudju imita mastite tossika akuta.

in the case of dairy cows, show no clinical evidence of mastitis;
fil-każ tal-baqar tal-ħalib, li ma juru l-ebda evidenza klinika ta' mastitis;

do not treat cows with palpable udder changes due to chronic subclinical mastitis.
tikkurax baqar li f’driegħhom jinħass tibdil ikkawżat minn mastite kronika mingħajr sintomi.

for adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.
għal terapija addizzjonali fit-trattament ta’ mastite akuta, flimkien ma’ terapija antibijotika adattata.

metacam was comparable to the control product in providing supportive treatment of acute mastitis in cattle.
metacam kien komparabbli mal-prodott ta' kontroll fil-provvediment ta' kura ta' appoġġ tal-mastite akuta fil-frat.

the antibodies will help to fight the bacteria, preventing mastitis occurring or reducing the severity of its symptoms.
l-antikorpi jgħinu fil-ġlieda kontra l-batterji, jipprevjenu milli sseħħ il-mastite jew inaqqsu s-severità tas-sintomi tagħha.

during this eu study, 312 cows were treated with imrestor for every 10 cases of clinical mastitis that were prevented during the periparturient period.
matul dan l-istudju tal-ue, 312-il baqra kienu kkurati b’imrestor għal kull 10 każijiet ta’ mastite klinika li kienu pprevenuti matul il-perjodu qabel u wara li jwelldu.

as an aid in a herd management programme, to reduce the risk of clinical mastitis in periparturient dairy cows and heifers during the 30 days following calving.
bħala għajnuna fi programm ta’ ġestjoni tal-merħla, biex jitnaqqas ir-riskju ta’ mastite klinika f’baqar tal-ħalib qabel u wara li jwelldu u erieħ matul it-30 jum wara t-twelid.

the studies showed that startvac reduced the number of cows with mastitis due to staphylococcus aureus and related bacteria and it reduced the severity of the symptoms in the cows that had mastitis.
l-istudji wrew li startvac naqqas in-numru ta’ baqar bil-mastite minħabba staphylococcus aureus u batterji relatati u naqqas is-severità tas-sintomi fil-baqar li kellhom il-mastite.

for adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis- metritisagalactia syndrome) with appropriate antibiotic therapy.
għal terapija addizzjonali fit-trattament ta’ settiċemija puwerperali u tossemija (sindrome mastite-metrite- agalaktja) flimkien ma’ terapija antibijotika adattata.

vaccination with startvac also led to an increased number of cows being cured of the infection, a reduction in the number of cows that needed treatment for mastitis, and an increase in the quantity and quality of milk production.
it- tilqim bi startvac wassal ukoll għal numru akbar ta’ baqar li kienu qed jiġu kkurati mill- infezzjoni, tnaqqis fin-numru ta’ baqar li kellhom bżonn it-trattament għall-mastite, u żieda fil-kwantità u l-kwalità tal-produzzjoni tal-ħalib.

for adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis- agalactia syndrome) with appropriate antibiotic therapy.
għal terapija addizzjonali fit-trattament ta’ settiċemija puwerperali u tossemija (sindrome mastite- metrite-agalaktja) flimkien ma’ terapija antibijotika adattata.

for adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis- agalactia syndrome mma) with appropriate antibiotic therapy.
għal terapija addizzjonali fil-kura ta’ settiċemija puwerperali u tossemija (sindrome mastite-metrite- agalaktja - mma) flimkien ma’ terapija antibijotika adattata.

milk analysis must be made not more than thirty days before loading and must always include a bacteriological test and a white side test (wst) or california mastitis test (cmt).
analiżi tal-ħalib għandha ssir mhux iktar tard minn tletin ġurnata qabel it-tagħbija u trid dejjem tinkludi test bioloġiku u test tal-Ġenb abjad (tĠa) jew test mastitis tal-kalifornja (tmk).

for the treatment of subclinical mastitis in lactating cows due to gram-positive cocci susceptible to pirlimycin including staphylococcal organisms such as staphylococcus aureus, both penicillinase- positive and penicillinase-negative, and coagulase-negative staphylococci; streptococcal organisms including streptococcus agalactiae, streptococcus dysgalactiae and streptococcus uberis.
għal kura ta’ mastite mingħajr sintomi, f’baqar li qed jaħilbu, ikkawżata minn kokki gram-positive li jirrispondu għall-pirlimycin, u dawn jinkludu mikrobi stafilokoċċi bħal staphylococcus aureus, kemm l-istafilokoċċi penicillinase-positive kif ukoll penicillinase-negative u coagulase-negative; mikrobi streptokoċċi li jinkludu streptococcus agalactiae, streptococcus dysgalactie u streptococcus uberis.